sk-cef 1 gm injection is administered intravenously (IV) or intramuscularly (IM). For IV administration, the powder is reconstituted and then further diluted for slow infusion over 30 minutes. For IM administration, it is reconstituted with appropriate diluent (e.g., Lidocaine for pain reduction) and injected deeply into a large muscle mass. Should be administered by a healthcare professional.

Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) located in the bacterial cell wall. This binding prevents the cross-linking of peptidoglycan units, leading to structural damage, osmotic instability, and ultimately lysis and death of the bacterial cell.

• •Hypersensitivity to ceftriaxone, other cephalosporins, or any component of the formulation.
• •History of severe hypersensitivity reaction to any penicillin (e.g., anaphylaxis).
• •Neonates (especially premature) with hyperbilirubinemia, as ceftriaxone can displace bilirubin from albumin binding sites.
• •Concomitant use with calcium-containing IV solutions in neonates (≤28 days of age).

Store dry powder vials below 30°C (preferably 15-30°C). Protect from light and moisture. Do not freeze. Keep out of reach of children. Reconstituted solutions should be stored as per manufacturer's guidelines, typically at room temperature for a short period or refrigerated for slightly longer, and protected from light.

In case of overdose, ceftriaxone concentrations can be reduced by hemodialysis or peritoneal dialysis. However, these methods are generally not very effective. Treatment should be symptomatic and supportive, focusing on maintaining vital functions and managing any adverse reactions.

Pregnancy Category B. Animal reproduction studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Ceftriaxone is excreted in low concentrations in breast milk; caution should be exercised when administered to a nursing woman.